Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tempest TherapeuticsTPST -3.31%32 Cash-to-Debt is 0.23 as of Mar. 2026, which is 86% below its 10-year median of 1.64. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Tempest Therapeutics ranks worse than 91.36% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tempest Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.23.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Tempest Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Tempest Therapeutics's Cash-to-Debt or its related term are showing as below:
TPST'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 1.64 Max: 7.72
Current: 0.23
During the past 6 years, Tempest Therapeutics's highest Cash to Debt Ratio was 7.72. The lowest was 0.23. And the median was 1.64.
TPST's Cash-to-Debt is ranked worse than 91.36% of 1400
companies
in the Biotechnology industry
Industry Median: 6.315
vs TPST: 0.23
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Tempest Therapeutics Cash-to-Debt Related Terms
Tempest Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Tempest Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Tempest Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tempest Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tempest Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics (TPST) has a Cash-to-Debt of 0.23 as of Mar. 2026. This is 86% below median its historical median of 1.64. Over the past decade, Tempest Therapeutics' Cash-to-Debt has ranged from 0.23 to 7.72. According to the industry distribution chart, Tempest Therapeutics ranks #1279 out of 1400 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Tempest Therapeutics' Cash-to-Debt too high?
Tempest Therapeutics' current Cash-to-Debt of 0.23 is 86% below median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 7.72. The Biotechnology industry median Cash-to-Debt is 6.32. Tempest Therapeutics' value of 0.23 is 96.4% below this industry median. Based on the distribution chart, Tempest Therapeutics ranks #1279 out of 1400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Cash-to-Debt compare to ICU and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #1279 out of 1400 companies for Cash-to-Debt. This places Tempest Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.32. Tempest Therapeutics' value of 0.23 is 96.4% below this benchmark. Historically, Tempest Therapeutics' own Cash-to-Debt has ranged from 0.23 to 7.72 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 6.32, Tempest Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.32, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tempest Therapeutics's current Cash-to-Debt of 0.23 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tempest Therapeutics's current Cash-to-Debt is 0.23, which is 86% below median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Cash-to-Debt of 0.23. The current Cash-to-Debt is 0.23, which is 86% below median its 10-year median of 1.64 and 96.4% below the Biotechnology industry median of 6.32. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Cash-to-Debt is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score
Get the complete analysis for TPST
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPST has been successfully added to your 
